Author's posts
A Technicality Could Keep RSV Shots From Kids in Need
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it’s not technically a vaccine.
FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas
While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.
$38,398 for a Single Shot of a Very Old Cancer Drug
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?
Pharma-Funded FDA Gets Drugs Out Faster, But Some Work Only ‘Marginally’ and Most Are Pricey
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.
Big Pharma Went All In to Kill Drug Pricing Negotiations
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn’t materialized.
What the Polio Case in New York Tells Us About the End of Polio
The Rockland County case isn’t expected to cause a major outbreak, but it shows how even this rare disease can pop up in undervaccinated communities.
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
Existing drugs still treat most infections. But that has discouraged investment in new drugs that will be needed when — not if —the old ones fail.
How Pfizer Won the Pandemic, Reaping Outsize Profit and Influence
The drugmaker has the best-selling vaccine to prevent covid and the most effective drug to treat it. Its success and might have overshadowed the government’s covid-fighting strategy.
Why Cheap, Older Drugs That Might Treat Covid Never Get Out of the Lab
The hydroxychloroquine and ivermectin fiascoes have soured many doctors on repurposing drugs for covid. A few inexpensive old drugs may be as good as some of the new antivirals, but they face complex obstacles to get to patients.
